Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| GRAIL | 8 | - | -0,23 % | ||
| AMICUS THERAPEUTICS | 4 | 1 | 0,00 % | ||
| SAVARA | 3 | - | 0,00 % | ||
| VANDA PHARMACEUTICALS | 3 | - | +2,04 % | ||
| MODERNA | 2 | 16 | +0,44 % | ||
| BIONTECH | 2 | 13 | +2,19 % | ||
| MADRIGAL PHARMACEUTICALS | 2 | 7 | -1,57 % | ||
| VIR BIOTECHNOLOGY | 2 | 2 | -3,32 % | ||
| AMGEN | 1 | 27 | +0,13 % | ||
| REGENERON PHARMACEUTICALS | 1 | 22 | -0,18 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13:59 | Abivax Reports Obefazimod's Anti-Fibrotic Potential And Rapid Symptom Relief In Crohn's Disease | 7 | RTTNews | ||
| 13:26 | Jefferies Raises its Price Target on Krystal Biotech, Inc. (KRYS) to $371 and Maintains a Buy Rating | 2 | Insider Monkey | ||
| 13:15 | Bayer Aktie: Alles vorbei? - Airbus, BB Biotech, BioNTech, TUI und Valneva - Börse Frankfurt | 667 | 4investors | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| 12:03 | EQS-News: ABIVAX: Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026 | 354 | EQS Group (EN) | EQS-News: ABIVAX
/ Key word(s): Study results
Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory... ► Artikel lesen | |
| 10:50 | ANAVEX LIFE SCIENCES CORP: Stabilität im Fokus | 2 | Maximilian Berger | ||
| 07:58 | 71% Potenzial! Warum Tempus AI Anleger reizt | 16 | Investing.com Deutsch | ||
| 03:48 | Vanda surges as FDA approves Bysanti for bipolar disorder, schizophrenia | 13 | Seeking Alpha | ||
| 00:06 | FDA approves Vanda's Bysanti for bipolar disorder, schizophrenia | 10 | Investing.com | ||
| Fr | Vanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Announces FDA Approval of BYSANTI (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New Horizons in Psychiatric Innovation | 333 | PR Newswire | WASHINGTON, Feb. 20, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved... ► Artikel lesen | |
| Fr | BioMarin Pharmaceutical Q4 2025 Earnings Preview | 2 | Seeking Alpha | ||
| Fr | Summit Therapeutics Q4 2025 Earnings Preview | 2 | Seeking Alpha | ||
| Fr | Vir Biotechnology Q4 2025 Earnings Preview | 1 | Seeking Alpha | ||
| Fr | Strong Analyst Confidence in C4 Therapeutics (CCCC)'s Cemsidomide Drives 270% Upside Potential | 1 | Insider Monkey | ||
| Fr | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | 8 | GlobeNewswire (USA) | ||
| Fr | The Analyst Verdict: Amgen In The Eyes Of 18 Experts | 4 | Benzinga.com | ||
| Fr | Expert Outlook: Beam Therapeutics Through The Eyes Of 4 Analysts | 1 | Benzinga.com | ||
| Fr | 5 Analysts Assess GRAIL: What You Need To Know | 5 | Benzinga.com | ||
| Fr | FDA to review Savara resubmitted Molbreevi BLA | 1 | Seeking Alpha | ||
| Fr | FDA nimmt Zulassungsantrag von Savara für Medikament gegen seltene Lungenkrankheit an | 2 | Investing.com Deutsch | ||
| Fr | FDA accepts Savara's drug application for rare lung disease | 3 | Investing.com |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.